2018
The effect of age and smoking on the hippocampus and memory in late middle age
Hawkins KA, Emadi N, Pearlson GD, Taylor B, Khadka S, King D, Blank K. The effect of age and smoking on the hippocampus and memory in late middle age. Hippocampus 2018, 28: 846-849. PMID: 30070068, DOI: 10.1002/hipo.23014.Peer-Reviewed Original ResearchConceptsSmoking historyHippocampal volumeHeavy smoking historyVascular risk factorsMiddle-aged subjectsMRI brain scanningAPOE e4 genotypeEffect of ageHeavy smokingHippocampal atrophyAlcohol historyRisk factorsE4 genotypeBrain scanningAPOE e4Neuropsychological assessment batteryHippocampus atrophyFemale subjectsGlobal cognitionMemory disordersData extractionMemory declineAssessment BatteryAgeSmokingCognition among individuals along a spectrum of increased risk for Parkinson’s disease
Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D, Initiative T. Cognition among individuals along a spectrum of increased risk for Parkinson’s disease. PLOS ONE 2018, 13: e0201964. PMID: 30125297, PMCID: PMC6101368, DOI: 10.1371/journal.pone.0201964.Peer-Reviewed Original ResearchConceptsParkinson's diseaseIdiopathic REM sleep behavior disorderParkinson's Progression Markers Initiative (PPMI) studyDe novo Parkinson's diseaseREM sleep behavior disorderDopamine transporterNon-motor symptomsNovo Parkinson's diseaseSleep behavior disorderNon-motor featuresSymbol Digit Modalities TestBaseline neuropsychological performanceMontreal Cognitive AssessmentFuture neurodegenerationLewy bodiesInclusion criteriaSpectrum of riskMutation carriersInitiative studyCohortBehavior disorderCognitive functionCognitive test scoresModalities TestNeuropsychological performance
2015
Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings
Chahine M, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators T. Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Movement Disorders 2015, 31: 86-94. PMID: 26293177, PMCID: PMC4827252, DOI: 10.1002/mds.26373.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnxietyAttentionCocaineCognition DisordersCohort StudiesExecutive FunctionFemaleHumansLanguageMaleMemoryMiddle AgedNeurogenic BowelNeuropsychological TestsOlfaction DisordersParkinson DiseaseProtein BindingRadiopharmaceuticalsSelf ReportSeverity of Illness IndexStatistics, NonparametricSurveys and QuestionnairesTomography, Emission-Computed, Single-PhotonVisual PerceptionConceptsExecutive function/Global cognitionRelative impairmentSpecific cognitive domainsSpeed/attentionGlobal cognitive abilityNeuropsychological test batteryLower global cognitionFunction/Cognitive abilitiesCognitive domainsCognitive profileVisuospatial abilitiesLanguage domainsCognitive testingTest batteryCognitionNormative scoresMemoryLower mean scoresHealthy adultsNon-motor featuresIndividualsStudy findingsNon-motor symptoms
2012
Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study
Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K, Investigators T. Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study. Movement Disorders 2012, 27: 406-412. PMID: 22237833, PMCID: PMC6342466, DOI: 10.1002/mds.24892.Peer-Reviewed Original ResearchMeSH KeywordsAgedCohort StudiesConstipationFemaleHumansMaleMiddle AgedMood DisordersOlfaction DisordersParkinson DiseaseRisk FactorsConceptsNonmotor featuresProdromal featuresOlfactory testingRapid eye movement sleep behaviour disorder symptomsSyndrome StudyPennsylvania Smell Identification TestDopamine transporter imagingPercent of subjectsSmell Identification TestRisk of PDFuture neurodegenerationHyposmic subjectsOlfactory dysfunctionImpaired olfactionTransporter imagingMotor functionMotor featuresSmell testNeurological diagnosisUndiagnosed individualsHyposmiaScreening testSpecific markersDisorder symptomsFurther assessment
2011
The Parkinson Progression Marker Initiative (PPMI)
Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Klinik P, Sherer T, Frasier M, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick S, Schuff N, Zhang Y, Toga A, Crawford K, Ansbach A, De Blasio P, Piovella M, Trojanowski J, Shaw L, Singleton A, Hawkins K, Eberling J, Brooks D, Russell D, Leary L, Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams K, Standaert D, Guthrie S, Hauser R, Delgado H, Jankovic J, Hunter C, Stern M, Tran B, Leverenz J, Baca M, Frank S, Thomas C, Richard I, Deeley C, Rees L, Sprenger F, Lang E, Shill H, Obradov S, Fernandez H, Winters A, Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, Gerstenhaber M, Brooks D, Malloy S, Barone P, Longo K, Comery T, Ravina B, Grachev I, Gallagher K, Collins M, Widnell K, Ostrowizki S, Fontoura P, Ho T, Luthman J, van der Brug M, Reith A, Taylor P, Initiative T. The Parkinson Progression Marker Initiative (PPMI). Progress In Neurobiology 2011, 95: 629-635. PMID: 21930184, PMCID: PMC9014725, DOI: 10.1016/j.pneurobio.2011.09.005.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeProgression Markers InitiativeProgression biomarkersCerebrospinal fluidMulti-center studyTherapeutic trialsPPMI cohortHealthy subjectsBiomarker assessmentClinical sitesStudy databaseReview CommitteeDisease etiologyLongitudinal collectionComprehensive observationalBiomarkersStudy dataAcquisition protocolsLikelihood of successEtiologyCohortBlood
2010
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. The Journal Of Clinical Psychiatry 2010, 71: 463-74. PMID: 20156410, PMCID: PMC3109728, DOI: 10.4088/jcp.07m03890yel.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAmbulatory CareAntipsychotic AgentsCohort StudiesCommunity Mental Health CentersConnecticutDiagnostic and Statistical Manual of Mental DisordersDyskinesia, Drug-InducedFemaleHumansIncidenceLongitudinal StudiesMaleMental DisordersMiddle AgedPrevalenceProspective StudiesPsychiatric Status Rating ScalesRisk FactorsSeverity of Illness IndexConceptsProspective cohort studyConventional antipsychoticsTardive dyskinesiaAtypical antipsychoticsCohort studyPrevious prospective cohort studyCommunity mental health centerConventional antipsychotic medicationsMental health centersAntipsychotic medicationHealth centersBaseline evaluationAntipsychoticsNew diagnosisDyskinesiaClinical practicePsychiatric outpatientsRecent exposureIncidencePrevious visitPrevious studiesPrevalenceSubjectsCurrent studyMost previous studies